Vima Therapeutics has announced significant progress in the development of its experimental treatment for movement disorders, revealing that the first patient has been dosed in a Phase 2 clinical trial evaluating VIM0423 for isolated dystonia. The clinical-stage biotechnology company also disclosed that it has expanded its Series A financing to $100 million to support the advancement of the therapy and broader research efforts.
The extended financing round includes new participation from Frazier Life Sciences along with existing investors Atlas Venture, Access Industries, and Canaan Partners. As part of the investment, Joe Cabral, a partner at Frazier Life Sciences, will join Vima Therapeutics’ board of directors. According to the company, the additional funding will help support two ongoing Phase 2 trials for VIM0423—one targeting isolated dystonia and another planned study in Parkinson’s disease.
The company expects to begin the Phase 2 clinical trial in Parkinson’s disease by mid-2026. Topline data from both the dystonia and Parkinson’s disease trials are anticipated in the first half of 2027.
VIM0423 is being developed as a potential first-in-class, once-daily oral therapy designed to treat movement disorders by selectively targeting muscarinic cholinergic receptors in the brain. These receptors are known to play a role in regulating the balance between dopamine and acetylcholine signaling—two neurotransmitters that are closely linked to motor control. Disruptions in this balance are believed to contribute to disorders such as dystonia and Parkinson’s disease.
Prior to entering Phase 2 testing, VIM0423 completed a two-part Phase 1 clinical study that evaluated the drug’s pharmacokinetics, safety, tolerability, and dose titration. The trial involved both healthy volunteers and individuals living with dystonia. According to the company, the therapy demonstrated a favorable safety profile and was well tolerated across both single-dose and multiple-dose cohorts over a 28-day period. Researchers also reported that the study met and exceeded target exposure levels, supporting further clinical development.
Bernard Ravina, founder and chief executive officer of Vima Therapeutics, said the results from the early-stage trial provide confidence that VIM0423 may help address significant unmet medical needs in patients with movement disorders. As a neurologist, Ravina noted he has witnessed firsthand the limitations of current treatment options for patients with dystonia and Parkinson’s disease.
Experts in the field have also expressed optimism about the therapy’s potential. Cynthia L. Comella, professor of neurology at Rush University Medical Center and a member of Vima’s scientific advisory board, highlighted the potential benefits of an oral therapy for dystonia patients. Current treatment options often involve injections or surgical interventions, making an oral alternative particularly appealing for both patients and physicians.
Dystonia is a chronic neurological disorder characterized by involuntary muscle contractions that can affect different parts of the body. The condition impacts more than 160,000 adults and children in the United States alone. Because dystonia shares underlying biological mechanisms with Parkinson’s disease, therapies that target key neurotransmitter pathways may offer broader benefits across multiple movement disorders.
VIM0423 has already received Fast Track designation from the U.S. Food and Drug Administration for the treatment of isolated dystonia, a regulatory pathway intended to accelerate the development and review of drugs addressing serious conditions with unmet medical needs.
With new funding secured and clinical trials underway, Vima Therapeutics aims to further explore the potential of VIM0423 to provide a more effective and tolerable treatment option for patients living with debilitating movement disorders.